Fierce competition to be seen for next generation oral anticoagulants

Multinational pharmaceutical companies are stepping up their marketing in the domestic market of oral anticoagulants replacing warfarin as mainstay therapy, which is forecast to become more competitive than even, according to industry sources.

The new generation of oral anticoagulants (Bayer’s Xarelto, Boehringer Ingelheim’s Pradaxa and BMS-Pfizer’s Eliquis), which obtained market authorizat...